<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gene test interpretation: &lt;i&gt;RET &lt;/i&gt;(multiple endocrine neoplasia type 2 gene)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gene test interpretation: <i>RET </i>(multiple endocrine neoplasia type 2 gene)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gene test interpretation: <i>RET </i>(multiple endocrine neoplasia type 2 gene)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne Slavotinek, MBBS, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2003706186"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This monograph summarizes the interpretation of germline genetic testing of <em>RET</em>, the gene associated with multiple endocrine neoplasia type 2 (MEN2). Affected individuals are heterozygous for a pathogenic variant in<em> RET</em>. Evaluation and management of MEN are discussed in detail separately [<a href="#rid1">1</a>]. (See <a class="local">'Information about MEN2'</a> below.)</p><p class="headingAnchor" id="H3155546105"><span class="h2"><i>RET</i> gene</span><span class="headingEndMark"> — </span>The rearranged during transfection (RET) proto-oncogene is a transmembrane glycoprotein receptor with tyrosine kinase activity that transduces growth and differentiation signals in several developing tissues, including those derived from the neural crest. Pathogenic, germline variants in <em>RET</em> resulting in gain-of-function cause MEN2, whereas somatic <em>RET</em> mutations are associated with sporadic medullary thyroid cancers. <em>RET</em> rearrangements may also occur in other cancers. The majority of pathogenic variants in <em>RET</em> involve one of five cysteine residues in the cysteine-rich region of the RET protein's extracellular domain. These residues are encoded in exons 10 (codons 609, 611, 618, and 620) or 11 (codon 634) in the <em>RET</em> gene  (<a class="graphic graphic_figure graphicRef71594" href="/d/graphic/71594.html" rel="external">figure 1</a>). Transmission is autosomal dominant; heterozygosity for a pathogenic or likely pathogenic variant in the <em>RET</em> gene is sufficient to cause MEN2. The pathogenic variant in <em>RET</em> is de novo in 5 to 15 percent and 50 percent of patients with MEN2A and MEN2B, respectively [<a href="#rid2">2</a>]. Thus, a negative family history should not be used to exclude the diagnosis. (See  <a class="medical medical_review" href="/d/html/7869.html" rel="external">"Classification and genetics of multiple endocrine neoplasia type 2", section on 'Molecular genetics'</a>.) </p><p class="headingAnchor" id="H1390990985"><span class="h2">How to read the report</span><span class="headingEndMark"> — </span>It is essential to confirm that the result applies to the tested individual and determine whether testing was performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory (or other nationally certified laboratory); if this is not the case, testing should be repeated in a certified laboratory. </p><p>These and other caveats are summarized in the checklist  (<a class="graphic graphic_table graphicRef122437" href="/d/graphic/122437.html" rel="external">table 1</a>). </p><p class="headingAnchor" id="H1732271213"><span class="h2">Disease association</span><span class="headingEndMark"> — </span>MEN2 is characterized by the triad of medullary thyroid cancer (MTC), pheochromocytoma, and primary parathyroid hyperplasia. MEN2 is subclassified into two distinct syndromes: MEN2A (95 percent) and MEN2B (5 percent)  (<a class="graphic graphic_table graphicRef101551" href="/d/graphic/101551.html" rel="external">table 2</a>). </p><p>The diagnosis is generally suspected on clinical grounds and established by genetic testing that identifies a pathogenic, or likely pathogenic, variant in <em>RET</em>. If a pathogenic <em>RET </em>variant cannot be identified, it may be possible to make the diagnosis clinically, although an estimated 98 percent of patients with MEN2 are found to have a pathogenic variant in <em>RET </em>after genetic testing.</p><p class="headingAnchor" id="H1910194357"><span class="h3">Multiple endocrine neoplasia type 2A</span><span class="headingEndMark"> — </span>Within MEN2A, there are four clinical subtypes: classical MEN2A, MEN2A with cutaneous lichen amyloidosis (CLA), MEN2A with Hirschsprung disease (HD), and familial medullary thyroid cancer (FMTC).</p><p class="headingAnchor" id="H1455293420"><span class="h4">Classical MEN2A</span><span class="headingEndMark"> — </span>This is the most common subtype of MEN2A and is associated with a heritable predisposition to MTC, pheochromocytoma, and primary parathyroid hyperplasia. The respective frequency of these tumors in classical MEN2A is over 90 percent for MTC, approximately 10 to 50 percent for pheochromocytoma (which is often bilateral), and 10 to 30 percent for multigland parathyroid hyperplasia. MEN2A is typically associated with pathogenic variants in exon 10 and 11 of <em>RET</em>  (<a class="graphic graphic_figure graphicRef71594" href="/d/graphic/71594.html" rel="external">figure 1</a>). The frequency of the development of MTC, pheochromocytoma, and parathyroid hyperplasia depends upon the specific variant.</p><p class="headingAnchor" id="H3853588981"><span class="h4">MEN2A with cutaneous lichen amyloidosis</span><span class="headingEndMark"> — </span>Cutaneous lichen amyloidosis (CLA, also called lichen planus amyloidosis [LPA]) has been described in some kindreds with MEN2A, predominantly those with pathogenic variants affecting exon 11 and codon 634 of <em>RET</em>, and some with pathogenic variants affecting codon 804. The diagnosis of CLA may precede the onset of clinically evident MTC. Patients with this clinical subtype of MEN2A develop pheochromocytomas and parathyroid hyperplasia with a similar frequency as those with classical MEN2A. (See  <a class="medical medical_review" href="/d/html/7870.html" rel="external">"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2"</a>.)</p><p class="headingAnchor" id="H3081317920"><span class="h4">MEN2A with Hirschsprung disease</span><span class="headingEndMark"> — </span>HD is a motor disorder of the gut caused by the failure of neural crest cells to migrate completely during intestinal development. The resulting aganglionic segment of the colon fails to relax, causing a functional bowel obstruction. The co-occurrence of HD and MEN2A is predominantly associated with pathogenic variants involving codons 609, 611, 618, and 620 in exon 10 of <em>RET </em> (<a class="graphic graphic_figure graphicRef71594" href="/d/graphic/71594.html" rel="external">figure 1</a>)<em>. </em>In such patients, HD may be the first presentation of MEN2A. Patients with this variant of MEN2A develop MTC, pheochromocytomas, and parathyroid hyperplasia with a similar frequency as those with classical MEN2A. (See  <a class="medical medical_review" href="/d/html/5903.html" rel="external">"Congenital aganglionic megacolon (Hirschsprung disease)"</a>.)</p><p class="headingAnchor" id="H2156483717"><span class="h4">Familial medullary thyroid cancer</span><span class="headingEndMark"> — </span>FMTC is a variant of MEN2A in which there is a strong predisposition to MTC, but not the other clinical manifestations of MEN2A (or 2B). The following criteria are used:</p><p class="bulletIndent1"><span class="glyph">●</span>More than 10 carriers in the kindred</p><p class="bulletIndent1"><span class="glyph">●</span>Multiple carriers or affected members age &gt;50 years</p><p class="bulletIndent1"><span class="glyph">●</span>An adequate medical history, particularly in older family members</p><p></p><p class="headingAnchor" id="H871501204"><span class="h3">Multiple endocrine neoplasia type 2B</span><span class="headingEndMark"> — </span>Individuals with MEN2B are at increased risk of MTC and pheochromocytoma, but parathyroid hyperplasia is not a feature of this disorder  (<a class="graphic graphic_table graphicRef101551" href="/d/graphic/101551.html" rel="external">table 2</a>). </p><p>Patients with MEN2B tend to have mucosal neuromas, typically involving the lips and tongue, and intestinal ganglioneuromas. Disturbances of colonic function are common, including chronic constipation and megacolon. Many of these patients have developmental challenges, a Marfanoid habitus, and myelinated corneal nerves. MEN2B is typically associated with the methionine to threonine (p.Met918Thr) missense variant within the activation segment of RET kinase in exon 16 of the gene.</p><p class="headingAnchor" id="H1650706218"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H439036750"><span class="h2">Pathogenic variant in <i>RET</i></span><span class="headingEndMark"> — </span>Optimal management for individuals with a pathogenic variant in <em>RET</em> involves a multidisciplinary team (see <a class="local">'Locating an expert'</a> below). The location of the pathogenic variant within the gene is important and a genotype-phenotype correlation is well established. Patients can be classified into highest risk, high risk, and moderate risk with timing of surgery adjusted accordingly  (<a class="graphic graphic_table graphicRef71392" href="/d/graphic/71392.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef77855" href="/d/graphic/77855.html" rel="external">table 4</a>).</p><p class="headingAnchor" id="H2790157940"><span class="h3">Medullary thyroid cancer</span></p><p class="headingAnchor" id="H381212292"><span class="h4">Screening and prophylactic thyroidectomy</span><span class="headingEndMark"> — </span>Virtually all patients with MEN2 develop clinically significant medullary thyroid cancer (MTC), often early in life. Individuals with a pathogenic <em>RET</em> variant should be screened for MTC with annual physical examination, neck ultrasound, and measurement of serum calcitonin from an early age. Prophylactic thyroidectomy should be performed before MTC develops or when it is still confined to the thyroid gland. The suggested timing of thyroidectomy is based upon evidence of age-dependent and codon-specific progression of early MTC  (<a class="graphic graphic_table graphicRef71392" href="/d/graphic/71392.html" rel="external">table 3</a>). As mentioned above, <em>RET</em> variants can be categorized as highest, high, and moderate risk, referring to the potential risk for local and distant MTC metastases at an early age. The table summarizes risk of MTC with different <em>RET</em> variants, age to initiate monitoring for MTC, and age recommendations for performing prophylactic thyroidectomy  (<a class="graphic graphic_table graphicRef71392" href="/d/graphic/71392.html" rel="external">table 3</a>). </p><p class="headingAnchor" id="H3459203301"><span class="h4">Patients with MTC</span><span class="headingEndMark"> — </span>For patients with MEN2 with MTC, total thyroidectomy is recommended. (See  <a class="medical medical_review" href="/d/html/7870.html" rel="external">"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2", section on 'Medullary thyroid cancer'</a> and  <a class="medical medical_review" href="/d/html/7866.html" rel="external">"Approach to therapy in multiple endocrine neoplasia type 2", section on 'Medullary thyroid cancer'</a>.)</p><p class="headingAnchor" id="H3337472148"><span class="h3">Pheochromocytoma screening</span><span class="headingEndMark"> — </span>Screening for pheochromocytoma is mandatory in all patients with MEN2. In particular, screening is indicated before thyroidectomy and in patients who are considering pregnancy to avoid a potential hypertensive crisis. The surgical management of unilateral and bilateral pheochromocytomas is discussed in detail separately  (<a class="graphic graphic_table graphicRef77855" href="/d/graphic/77855.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/7870.html" rel="external">"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2", section on 'Pheochromocytoma'</a> and  <a class="medical medical_review" href="/d/html/7866.html" rel="external">"Approach to therapy in multiple endocrine neoplasia type 2", section on 'Pheochromocytoma'</a>.)</p><p class="headingAnchor" id="H1932006020"><span class="h3">Primary hyperparathyroidism in MEN2A</span><span class="headingEndMark"> — </span>Screening for primary hyperparathyroidism with (ionized) calcium or serum calcium with albumin and intact parathyroid hormone (PTH) is recommended in patients with MEN2A. The age to begin screening (11 to 16 years) depends on the location of the pathogenic variant; screening is typically commenced at the same age as screening for pheochromocytoma  (<a class="graphic graphic_table graphicRef77855" href="/d/graphic/77855.html" rel="external">table 4</a>). When the diagnosis of MEN2A-related MTC is established, we recommend measuring serum calcium to rule out hyperparathyroidism requiring concomitant surgical intervention. Indications for surgical intervention are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7866.html" rel="external">"Approach to therapy in multiple endocrine neoplasia type 2", section on 'Primary hyperparathyroidism'</a> and  <a class="medical medical_review" href="/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management"</a>.)</p><p class="headingAnchor" id="H2220003618"><span class="h3">Hirschsprung disease</span><span class="headingEndMark"> — </span>The treatment for HD is surgical resection of the aganglionic segment of bowel. (See  <a class="medical medical_review" href="/d/html/5903.html" rel="external">"Congenital aganglionic megacolon (Hirschsprung disease)", section on 'Management'</a>.)</p><p class="headingAnchor" id="H2371866581"><span class="h3">Cutaneous lichen amyloidosis</span><span class="headingEndMark"> — </span>There is no effective treatment for cutaneous amyloidosis.</p><p class="headingAnchor" id="H1954590672"><span class="h2">Variant of uncertain significance (VUS) or negative genetic testing</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Negative genetic testing for a known familial pathogenic variant in </strong><strong><em>RET</em></strong><em> </em>– Negative testing for a known familial pathogenic variant in <em>RET </em>very likely excludes MEN2, with caveats noted above. (See <a class="local">'How to read the report'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Negative genetic testing if familial </strong><strong><em>RET </em></strong><strong>variant unknown</strong> –<em> </em>If MEN2 is suspected based on personal or family history and a familial variant in <em>RET</em> has <strong>not</strong> been characterized, then negative testing of <em>RET</em> cannot be used to exclude the disorder. Consultation with a genetics expert is advised to determine the next steps, which may include gene panel testing for other genes or more extensive testing of <em>RET</em>. Biochemical testing can also be performed to detect MEN2-related tumors and includes testing serum calcitonin (with or without pentagastrin or calcium stimulation), plasma fractionated metanephrines, and serum calcium. If biochemical testing is used, then yearly testing starting at age five and continuing until at least age 35 years (or until a positive test occurs) is necessary. (See  <a class="medical medical_review" href="/d/html/7870.html" rel="external">"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2"</a> and  <a class="medical medical_review" href="/d/html/7870.html" rel="external">"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2", section on 'When RET mutation is unknown'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Variant of uncertain significance (VUS)</strong> – A VUS means the pathogenicity of the variant has not been determined. Management is based on personal and family history of MEN2 manifestations. Individuals with a VUS may benefit from consultation with an expert in MEN2 or a genetics expert to assist in determining the significance of the variant.</p><p></p><p class="headingAnchor" id="H412051474"><span class="h2">First-degree relatives</span><span class="headingEndMark"> — </span>All first-degree relatives of an individual with a pathogenic variant in<em> RET</em> should be offered genetic counseling and testing for the variant. The parents of the proband should be tested if future childbearing is possible. It is possible that a parent may be affected but undiagnosed. It is also possible that the individual has a de novo germline pathogenic variant and the parent may be unaffected  (<a class="graphic graphic_algorithm graphicRef141355" href="/d/graphic/141355.html" rel="external">algorithm 1</a>). (See <a class="local">'RET gene'</a> above.)</p><p>MEN2 is inherited as an autosomal dominant trait. Each child of an affected parent has a 50 percent chance of inheriting the <em>RET </em>variant and being at risk for developing MEN2. Genetic testing should be performed at birth or very soon thereafter to determine the surveillance that is needed. Early diagnosis by screening "at-risk" family members in MEN2 kindreds is essential because MTC is a life-threatening disease that can be cured or prevented by early thyroidectomy.</p><p>Reproductive counseling should be provided for affected individuals to discuss reproductive options. Some may elect to conceive using donor gametes or in vitro fertilization (IVF) with preimplantation genetic testing (PGT). (See  <a class="medical medical_review" href="/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions", section on 'When are donor oocytes used?'</a> and  <a class="medical medical_review" href="/d/html/7423.html" rel="external">"Donor insemination"</a> and  <a class="medical medical_review" href="/d/html/6783.html" rel="external">"Preimplantation genetic testing"</a>.)</p><p class="headingAnchor" id="H3884806527"><span class="h1">RESOURCES</span></p><p class="headingAnchor" id="H3371167979"><span class="h2">Information about MEN2</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>UpToDate topics</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genetics – (See  <a class="medical medical_review" href="/d/html/7869.html" rel="external">"Classification and genetics of multiple endocrine neoplasia type 2"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Clinical features and diagnosis – (See  <a class="medical medical_review" href="/d/html/7870.html" rel="external">"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2"</a> and  <a class="medical medical_review" href="/d/html/5903.html" rel="external">"Congenital aganglionic megacolon (Hirschsprung disease)"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Treatment – (See  <a class="medical medical_review" href="/d/html/7866.html" rel="external">"Approach to therapy in multiple endocrine neoplasia type 2"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Guidelines – (See  <a class="medical medical_society_guidelines" href="/d/html/117633.html" rel="external">"Society guideline links: Medullary thyroid cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MEN2 resources</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Frarediseases.org%2Fnon-member-patient%2Famerican-multiple-endocrine-neoplasia-support%2F&amp;token=wGQUQAgn6p1rCDniOJZeWnexMbrxumzmBiAD2b2QKQ4O3LN7%2FEMqZtGXJFlnPVE2JhQB15OBT0tWCW8GQ01LECUfRpWEDyqowJVLnOoGteE%3D&amp;TOPIC_ID=138384" target="_blank">American Multiple Endocrine Neoplasia Support group</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Frarediseases.org%2F&amp;token=9E9IX7kiH9qRiTPgEvfhBeYjQOtPjl2OjGky4jLGFuLb510NH1k3XPz57jIaCL1j&amp;TOPIC_ID=138384" target="_blank">National Organization of Rare Disorders (NORD)</a></p><p></p><p class="headingAnchor" id="H2211990896"><span class="h2">Locating an expert</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical geneticists</strong> – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=138384" target="_blank">American College of Medical Genetics and Genomics</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic counselors</strong> – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F%3Freload%3Dtimezone&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflzQ%2BZ4POBsSFXQiuwJDn5pefBPIAES8nVSzeVi4Tr3mXQ%3D%3D&amp;TOPIC_ID=138384" target="_blank">National Society of Genetic Counselors</a>. Genetic testing laboratories may also provide online or telephone access to a genetic counselor. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cancer.gov%2Fabout-cancer%2Fcauses-prevention%2Fgenetics%2Fdirectory&amp;token=j%2Fp%2BIZfImoJgnd%2Fk4T5MAbDlZmLADFk1VrVOJqDdPzf1mGWFw3YadpFlBYSMxNKDeExYMR0QNQoNISFKbh7RPtm%2BfHLonSi2ZDCqhRzTq0w%3D&amp;TOPIC_ID=138384" target="_blank">National Institutes of Health (NIH) Cancer Genetics Services Directory</a></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</li><li class="breakAll">Multiple Endocrine Neoplasia Type 2. GeneReviews. National Library of Medicine. National Institutes of Health. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1257/ (Accessed on July 12, 2022).</li></ol></div><div id="topicVersionRevision">Topic 138384 Version 2.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.ncbi.nlm.nih.gov/books/NBK1257/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Multiple Endocrine Neoplasia Type 2. GeneReviews. National Library of Medicine. National Institutes of Health. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1257/ (Accessed on July 12, 2022).</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
